E-Eye IRPL is an innovative medical technology designed for the treatment of dry eye syndrome caused by meibomian gland dysfunction.
The treatment uses regulated intense pulsed light (IRPL), applied to the periocular area, to act on the mechanisms involved in evaporative dry eye.
E-Eye® is available in the Republic of Moldova at Clinica Oculus Prim.
Meibomian glands are located along the eyelid margins and produce the lipid component of the tear film.
When the function of these glands is impaired, the lipid layer of the tear film can no longer adequately protect the ocular surface, and tears evaporate more quickly.
This mechanism can cause dryness, burning, foreign body sensation, eye fatigue, visual fluctuations and discomfort, especially during prolonged screen use.
In these situations, treatment should target not only temporary tear replacement, but also improvement of meibomian gland function.
The treatment is primarily aimed at the mechanisms involved in meibomian gland dysfunction and evaporative dry eye.
IRPL light pulses warm and stimulate meibomian gland secretion, reduce inflammation, promote the formation of a healthy tear film and relieve dry eye symptoms.
E-Eye® uses regulated intense pulsed light (IRPL), applied in a controlled manner to the periocular region.
Light energy is used to act on the mechanisms involved in meibomian gland dysfunction and evaporative dry eye.
Before the procedure, the area is properly prepared, and the patient is provided with eye protection.
Pulses are applied in a controlled manner to the treatment area, with attention to the periocular region and meibomian glands.
Dry eye can have different causes and mechanisms. Therefore, E-Eye® treatment is indicated after evaluation of the ocular surface and meibomian gland function.
E-Eye® treatment is performed in the clinic, according to a protocol established based on the patient's evaluation.
The E-Eye® protocol generally involves several sessions, performed at intervals recommended by the doctor.
Depending on the ocular condition and response to treatment, the doctor may establish an individualized protocol.
The goal of treatment is to improve symptoms and tear film stability by supporting meibomian gland function.
Results and the rate of improvement vary from patient to patient and depend on the cause and severity of the dysfunction.
E-Eye® IRPL is available in the Republic of Moldova at Clinica Oculus Prim, where evaluation and treatment are integrated into a medical approach to dry eye syndrome.
Before starting treatment, the doctor evaluates the characteristics of the dry eye and determines whether IRPL therapy is appropriate for the patient.
Answers to the most frequently asked questions about dry eye treatment with IRPL technology.
OCHELARI GUESS was successfully added to cart